Main Catalog

Found 92
Sort by
Nexus Conferences
Member $15.00
Non-Member $30.00

How is Real-World Evidence in Oncology Used by Payers in Decision-Making? Home Study

Contact Hours: 1 - Payers face significant and growing costs with oncology treatments.
Oncology
Nexus Conferences
Member Free
Non-Member $30.00

How Continued Drug Shortages Compromise Patient Care

Contact Hours: 1.5. Providing safe and effective drug therapy has become extremely challenging during extended periods of drug shortages.
Drug Shortages
Nexus Conferences
Member Free
Non-Member $30.00

Preventative Treatment for Alzheimer’s Disease and the Future Role of Value-Based Payment Arrangements

Contact Hours: 1.5. The current understanding of Alzheimer’s disease is evolving.
Alzheimer's
Nexus Conferences
Member Free
Non-Member $30.00

The Managed Care Evaluation of Non-Alcoholic Steatohepatitis Treatment Options

Contact Hours: 1.5. Non-alcoholic steatohepatitis (NASH) is a liver disease resulting from metabolic dysfunction that can lead to serious and costly health conditions, such as inflammation, hepatocellular injury, progressive fibrosis, and cirrhosis.
NASH
Nexus Conferences
Member Free
Non-Member $30.00

Increasing Positive Outcomes: The Impact of Social Determinants of Health

Contact Hours: 1.5. There is a growing body of evidence that highlights how social determinants of health—socioeconomic status, education, physical environment, employment, and social support networks—play a large role in determining overall health outcomes.
Social Determinants
Nexus Conferences
Member Free
Non-Member $30.00

Real-Time Pharmacy Benefits: Results and Learnings from a Real-World Implementation

Contact Hours: 1.5. Real-time pharmacy benefits (RTPB) deliver real-time access to medication pricing and restriction information at the point of prescribing.
Real-TIme Pharmacy
Nexus Conferences
Member Free
Non-Member $30.00

Checking In on Health Care Reform Efforts: What Do They Mean for Payers, Manufacturers, and Patients?

Contact Hours: 1.5. While broader drug pricing reform efforts have taken the lion’s share of attention in health policy discourse over the past year, the Trump Administration has continued to move forward with implementing changes to the Affordable Care Act (ACA).
Health Care Reform
Nexus Conferences
Member Free
Non-Member $30.00

Innovative Value-Based Contracting Approaches with Comprehensive Clinical Strategies

Contact Hours: 1.5. Innovative approaches to developing value-based contracts in the market need to be multi-faceted.
Value-Based Contracting
Nexus Conferences
Member Free
Non-Member $30.00

Fast and Furious: What is Driving the Specialty Spend?

Contact Hours: 1.5. In 2018, the United States spent an estimated $517 million on specialty drugs. While specialty medications make up only about 1–2 % of all prescriptions written, they account for nearly 50% of total drug spend.
Specialty Drug Spend
Nexus Conferences
Member Free
Non-Member $30.00

The Times They Are a-Changin – A Look at Congressional Efforts to Reform the Medicare and Medicaid Prescription Drug Programs

Contact Hours: 1.5. For more than a decade, millions of American seniors have been able to access prescription drugs through market-driven programs.
Prescription Drug Program